Fungal Skin Infections: Types, Symptoms, and Treatment

Fungal skin infections rank among the most prevalent dermatological conditions in the United States, affecting tens of millions of people annually across all age groups and skin types. These infections arise when pathogenic fungi colonize the outer layers of the skin, hair, or nails, producing a recognizable but often misidentified set of symptoms. Understanding the classification, mechanisms, and evidence-based treatment frameworks for fungal infections is essential for accurate diagnosis and appropriate clinical management, as covered across the skin conditions overview and related condition pages on this site.

Definition and Scope

Fungal skin infections are caused by organisms that exploit the keratin found in the skin's outermost layer, the stratum corneum, as well as in hair shafts and nail plates. The U.S. Centers for Disease Control and Prevention (CDC) classifies dermatophytoses, candidiasis, and tinea versicolor among the most common superficial fungal conditions affecting the general population.

Three primary fungal categories cause the vast majority of cutaneous disease:

1. Dermatophytes — A group of mold-like fungi including Trichophyton, Microsporum, and Epidermophyton genera. Dermatophytes are the causative agents of tinea infections (ringworm, athlete's foot, jock itch, nail infections).
2. Yeasts — Chiefly Candida albicans and Malassezia furfur. Candida species produce intertrigo and mucocutaneous infections; Malassezia causes tinea versicolor (also called pityriasis versicolor).
3. Molds — Non-dermatophyte molds such as Scopulariopsis brevicaulis can cause onychomycosis (nail fungus), particularly in immunocompromised patients.

The American Academy of Dermatology (AAD) notes that dermatophyte infections are named by the body site affected rather than the causative organism alone — a clinical convention that can obscure the shared fungal etiology.

How It Works

Fungal pathogens establish infection through a defined biological sequence. Dermatophytes, for example, adhere to desquamated keratinocytes on the skin surface, then secrete keratinolytic enzymes — proteinases and lipases — that digest keratin, allowing hyphal penetration into the stratum corneum. The infection typically remains confined to non-living keratinized tissue because an intact immune system prevents deeper invasion in healthy hosts.

Candida albicans operates through a different mechanism: it is part of the normal human microbiome but transitions to a pathogenic state when local conditions shift — elevated moisture, disrupted skin barrier, antibiotic-induced microbiome changes, or immunosuppression. Candidal intertrigo, for instance, preferentially develops in skin folds where occlusion raises both temperature and humidity above the thresholds that suppress its proliferation.

Malassezia furfur, the causative yeast of tinea versicolor, is lipophilic and concentrated in sebaceous follicle-rich regions. When it overgrows, it produces azelaic acid and other dicarboxylic acids that interfere with melanocyte function, producing the characteristic hypo- or hyperpigmented patches.

The host immune response — specifically cell-mediated immunity via T-lymphocytes — is the primary containment mechanism. Individuals with conditions affecting T-cell function, including HIV/AIDS or those receiving immunosuppressive therapy, face a substantially elevated risk of invasive or treatment-resistant fungal disease, as documented by the National Institute of Allergy and Infectious Diseases (NIAID).

Common Scenarios

Fungal infections present across a wide range of anatomical sites and demographic contexts. The most clinically significant presentations include:

Tinea Pedis (Athlete's Foot)
Trichophyton rubrum causes the majority of tinea pedis cases. The interdigital form — fissuring, maceration, and scaling between the toes — is the most recognizable presentation. The moccasin-type variant produces diffuse hyperkeratosis across the plantar surface and is often mistaken for eczema or psoriasis.

Tinea Capitis (Scalp Ringworm)
Predominant in children under age 12. Trichophyton tonsurans accounts for over 90 percent of tinea capitis cases in the United States, according to the CDC. Kerion formation — a boggy, painful inflammatory mass — can lead to permanent scarring alopecia if untreated. Systemic antifungals, not topical agents alone, are required for effective treatment.

Onychomycosis (Nail Fungus)
Affects approximately 14 percent of the general U.S. population (American Academy of Dermatology, Onychomycosis overview), with prevalence rising sharply in adults over age 60. Trichophyton rubrum is again the dominant pathogen. Distal subungual onychomycosis — yellowing, thickening, and onycholysis originating at the nail tip — is the most common subtype. Treatment requires prolonged systemic antifungal therapy because topical agents penetrate the nail plate poorly.

Tinea Versicolor
Affects an estimated 1–4 percent of the population in temperate climates and up to 50 percent in tropical environments with high humidity (NIAID). Lesions are often most apparent following sun exposure, when surrounding skin tans but affected areas do not.

Cutaneous Candidiasis
Commonly presents in skin folds (axillae, groin, inframammary areas) as erythematous plaques with satellite pustules. Predisposing factors include obesity, diabetes mellitus, and broad-spectrum antibiotic use. Diaper dermatitis in infants frequently has a Candida secondary component.

Decision Boundaries

Distinguishing fungal infections from morphologically similar conditions is a core diagnostic challenge. The regulatory context for dermatology relevant to laboratory testing and prescription antifungal use shapes how confirmed diagnoses are pursued in clinical practice.

Fungal vs. Non-Fungal Inflammatory Conditions

Potassium hydroxide (KOH) microscopy of skin scrapings remains the first-line diagnostic tool — rapid, low-cost, and specific when positive. Fungal culture on Sabouraud dextrose agar provides species-level confirmation but requires 2–4 weeks for results. Dermoscopy assists in evaluating nail involvement; for further detail on imaging techniques, the dermoscopy and skin imaging page covers clinical applications.

Treatment Selection by Pathogen Class

Antifungal agents are class-specific. Dermatophyte infections respond to allylamines (terbinafine) and azoles (clotrimazole, fluconazole, itraconazole). Candida infections are treated with azoles or polyenes (nystatin for mucocutaneous disease). Terbinafine has limited activity against Candida species and should not be substituted.

Duration is pathogen- and site-dependent:

1. Tinea pedis (interdigital): Topical terbinafine for 1 week or topical azole for 2–4 weeks.
2. Tinea capitis: Oral terbinafine or griseofulvin for 6–12 weeks; griseofulvin remains FDA-approved for pediatric use at weight-based dosing per FDA drug labeling.
3. Onychomycosis (toenail): Oral terbinafine 250 mg daily for 12 weeks is the current standard-of-care regimen recommended by the AAD (AAD Clinical Guidelines).
4. Tinea versicolor: Topical selenium sulfide, ketoconazole shampoo, or single-dose oral fluconazole 300–400 mg.
5. Cutaneous candidiasis: Topical azoles for uncomplicated cases; oral fluconazole for recurrent or extensive disease.

Recurrence rates for onychomycosis exceed 20 percent within 3 years after successful treatment (AAD), underscoring the importance of preventive measures — moisture control, antifungal powder use in footwear — alongside pharmacological intervention.

For conditions overlapping with nail involvement, the nail disorders and dermatology page provides additional structural context. For hair-shaft involvement in tinea capitis and its relationship to acquired alopecia, the alopecia and hair loss page offers relevant comparative detail. Topical antifungal agents are also addressed within the broader [topical medications in dermatology](/topical-medications-

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)